These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
202 related items for PubMed ID: 1456399
1. Screening for neuroblastoma in the northern region of England. Laboratory aspects. Seviour JA, McGill AC, Craft AW, Parker L, Bell S, Cole M, Smith J, Hawkins E, Brown J, Dale GA. Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):332-6. PubMed ID: 1456399 [Abstract] [Full Text] [Related]
6. Establishment of cut off values for vanillylmandelic acid and homovanillic acid in 24-hr urine accumulation during mass screening for neuroblastoma. Nishi M, Miyake H, Takeda T, Takasugi N, Sato Y, Hanai J. Jpn J Clin Oncol; 1987 Sep; 17(3):221-8. PubMed ID: 3669365 [Abstract] [Full Text] [Related]
7. Neuroblastoma screening: labeling of HVA and VMA for stable isotope dilution gas chromatography-mass spectrometry. Gleispach H, Huber E, Fauler G, Kerbl R, Urban C, Leis HJ. Nutrition; 1995 Sep; 11(5 Suppl):604-6. PubMed ID: 8748233 [Abstract] [Full Text] [Related]
10. Three years of experience with random urinary homovanillic and vanillylmandelic acid levels in the diagnosis of neuroblastoma. Tuchman M, Ramnaraine ML, Woods WG, Krivit W. Pediatrics; 1987 Feb; 79(2):203-5. PubMed ID: 3808793 [Abstract] [Full Text] [Related]
11. Urinary vanillylmandelic acid and homovanillic acid levels in randomly-sampled urine for the mass screening of neuroblastoma. Nishi M, Miyake H, Takeda T, Takasugi N, Hanai J, Kawai T. Jpn J Clin Oncol; 1990 Sep; 20(3):268-70. PubMed ID: 2255102 [Abstract] [Full Text] [Related]
13. Screening for neuroblastoma at 3 weeks of age: methods and preliminary results from the Quebec Neuroblastoma Screening Project. Tuchman M, Lemieux B, Auray-Blais C, Robison LL, Giguere R, McCann MT, Woods WG. Pediatrics; 1990 Nov; 86(5):765-73. PubMed ID: 2152340 [Abstract] [Full Text] [Related]
14. A pilot study of screening for neuroblastoma in the north of England. Craft AW, Parker L, Dale G, McGill AC, Seviour JA, Bell S, Cole M, Smith J. Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):337-41. PubMed ID: 1456400 [Abstract] [Full Text] [Related]
16. [Present status of neuroblastoma mass screening in Japan. Neuroblastoma-Committee of the Japanese Childhood Cancer Society]. Sawada T, Nagahara N, Ohi R, Yamamoto K, Okabe I, Hanawa Y, Hashizume K, Matsui I, Ohkawa H, Tunoda A. Gan To Kagaku Ryoho; 1990 Dec; 17(12):2319-26. PubMed ID: 2260868 [Abstract] [Full Text] [Related]
17. Past and future of neuroblastoma screening in Japan. Sawada T. Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):320-6. PubMed ID: 1456397 [Abstract] [Full Text] [Related]
18. HPLC-mass spectrometry method for quantitative detection of neuroendocrine tumor markers: vanillylmandelic acid, homovanillic acid and 5-hydroxyindoleacetic acid. Lionetto L, Lostia AM, Stigliano A, Cardelli P, Simmaco M. Clin Chim Acta; 2008 Dec; 398(1-2):53-6. PubMed ID: 18760269 [Abstract] [Full Text] [Related]
19. Screening for neuroblastoma in North America. 2-year results from the Quebec Project. Woods WG, Tuchman M, Bernstein ML, Leclerc JM, Brisson L, Look T, Brodeur GM, Shimada H, Hann HL, Robison LL. Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):312-9. PubMed ID: 1456396 [Abstract] [Full Text] [Related]
20. Analysis of vanillylmandelic acid and homovanillic acid by UPLC-MS/MS in serum for diagnostic testing for neuroblastoma. Sadilkova K, Dugaw K, Benjamin D, Jack RM. Clin Chim Acta; 2013 Sep 23; 424():253-7. PubMed ID: 23830883 [Abstract] [Full Text] [Related] Page: [Next] [New Search]